| Autor: |
Wu P; a Institute for Science and Technology in Medicine , Keele University, Guy Hilton Research Center , Staffordshire , UK.; b Academic Unit of Obstetrics and Gynecology, University Hospital of North Midlands NHS Trust , Stoke-on-Trent, Staffordshire , UK., Farrell WE; a Institute for Science and Technology in Medicine , Keele University, Guy Hilton Research Center , Staffordshire , UK., Haworth KE; a Institute for Science and Technology in Medicine , Keele University, Guy Hilton Research Center , Staffordshire , UK., Emes RD; c School of Veterinary Medicine and Science, University of Nottingham , Leicestershire , UK.; d Advanced Data Analysis Center , University of Nottingham , Leicestershire , UK., Kitchen MO; a Institute for Science and Technology in Medicine , Keele University, Guy Hilton Research Center , Staffordshire , UK., Glossop JR; a Institute for Science and Technology in Medicine , Keele University, Guy Hilton Research Center , Staffordshire , UK.; e Haywood Rheumatology Center, Haywood Hospital , Staffordshire , UK., Hanna FW; f Department of Diabetes and Endocrinology , University Hospital of North Midlands NHS Trust , Stoke-on-Trent, Staffordshire , UK., Fryer AA; a Institute for Science and Technology in Medicine , Keele University, Guy Hilton Research Center , Staffordshire , UK. |
| Abstrakt: |
Several recent reports have described associations between gestational diabetes (GDM) and changes to the epigenomic landscape where the DNA samples were derived from either cord or placental sources. We employed genome-wide 450K array analysis to determine changes to the epigenome in a unique cohort of maternal blood DNA from 11 pregnant women prior to GDM development relative to matched controls. Hierarchical clustering segregated the samples into 2 distinct clusters comprising GDM and healthy pregnancies. Screening identified 100 CpGs with a mean β-value difference of ≥0.2 between cases and controls. Using stringent criteria, 5 CpGs (within COPS8, PIK3R5, HAAO, CCDC124, and C5orf34 genes) demonstrated potentials to be clinical biomarkers as revealed by differential methylation in 8 of 11 women who developed GDM relative to matched controls. We identified, for the first time, maternal methylation changes prior to the onset of GDM that may prove useful as biomarkers for early therapeutic intervention. |
